Clinical observation of brucea javanica oil combined with 125I and chemotherapy on Stage Ⅲ-Ⅳ Pa-tients with non-small cell lung cancer
10.3760/cma.j.issn.1008-6315.2016.10.003
- VernacularTitle:鸦胆子油乳联合125 I粒子植入及化学治疗晚期非小细胞肺癌的临床观察
- Author:
Yupeng WANG
;
Lili NING
;
Jianhui XU
;
Ling HAN
;
Yongjin HU
;
Bo QU
;
Xueming DU
- Publication Type:Journal Article
- Keywords:
125I seed implantation;
TP chemotherapy regimen;
DDP;
Non-small cell lung canc-er;
Brucea javanica oil
- From:
Clinical Medicine of China
2016;32(10):872-875
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and side reaction of brucea javanica oil ( BJO) combined with 125I and chemotherapy on stageⅢ?Ⅳpatients with non?small cell lung cancer ( NSCLC) . Methods One hundred and twenty cases on stageⅢ?Ⅳpatients with NSCLC were randomly divided into two groups,60 cases received BJO combined with 125I and chemotherapy treatment(observation group),the other 60 cases received 125I combined with chemotherapy treatment(control group). Results The objective response rate(ORR) and disease control rate (DCR) were 71. 7%,86. 7% of observation group and 66. 7%,85. 0% of control group,there were no significant difference(χ2=0. 352,0. 069;P>0. 05) . The improvement rate of KPS score in observation group was significantly superior to that in control group, the difference was significant (76. 7% vs. 55. 0%;χ2=6. 261,P<0. 05) . The incidence of myelosuppression and gastrointestinal adverse e?vents in observation group was significantly lower that in control group ( 68. 3% vs. 83. 3%,41. 7% vs. 61. 7%;χ2=3. 883,4. 805;P<0. 05) . Conclusion BJO combined with 125I and chemotherapy for treating on stageⅢ?Ⅳ patients with NSCLC can reduce the toxicity and side effects caused by chemotherapy,and significantly im?prove the clinical symptoms and quality of life of patients.
